De Vriese AS, et al. The atrial fibrillation conundrum in dialysis patients. Am Heart J 2016; 174: 111–119. doi: 10.1016/j.ahj.2016.01.010

• PubMed
De Vriese AS, The atrial fibrillation conundrum in dialysis patients. Am Heart J 2016; 174: 111–119. doi: 10.1016/j.ahj.2016.01.010)| false
• Search Google Scholar
• Export Citation

Zimmerman D, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27: 3816–3822. doi: 10.1093/ndt/gfs416

• PubMed
Zimmerman D, Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27: 3816–3822. doi: 10.1093/ndt/gfs416)| false
• Search Google Scholar
• Export Citation

Findlay MD, et al. Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 2015; 46: 2477–2481. doi: 10.1161/STROKEAHA.115.009095

• PubMed
Findlay MD, Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 2015; 46: 2477–2481. doi: 10.1161/STROKEAHA.115.009095)| false
• Search Google Scholar
• Export Citation

De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: Evidence and opinion. Nephrol Dial Transplant [published online ahead of print February 27, 2021]. doi: 10.1093/ndt/gfab060; https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfab060/6153972?login=false

• PubMed
De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: Evidence and opinion. Nephrol Dial Transplant [published online ahead of print February 27, 2021]. doi: 10.1093/ndt/gfab060; https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfab060/6153972?login=false)| false
• Search Google Scholar
• Export Citation

De Vriese AS, et al. Safety and efficacy of vitamin K antagonists vs rivaroxaban in HD patients with atrial fibrillation: A multicenter randomized controlled trial. J Am Soc Nephrol 2021; 32: 1474–1483. doi: 10.1681/ASN.2020111566

• PubMed
De Vriese AS, Safety and efficacy of vitamin K antagonists vs rivaroxaban in HD patients with atrial fibrillation: A multicenter randomized controlled trial. J Am Soc Nephrol 2021; 32: 1474–1483. doi: 10.1681/ASN.2020111566)| false
• Search Google Scholar
• Export Citation

Wald R, et al. Benefits and risks of anticoagulation in dialysis patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2020; 75:286–288. doi: 10.1016/j.jacc.2019.11.033

• PubMed
Wald R, Benefits and risks of anticoagulation in dialysis patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2020; 75:286–288. doi: 10.1016/j.jacc.2019.11.033)| false
• Search Google Scholar
• Export Citation

Van Der Meersch H, et al. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J 2017; 184: 37–46. doi: 10.1016/j.ahj.2016.09.016

• PubMed
Van Der Meersch H, Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J 2017; 184: 37–46. doi: 10.1016/j.ahj.2016.09.016)| false
• Search Google Scholar
• Export Citation

Randhawa MS, et al. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: A systematic review and meta-analysis. JAMA Netw Open 2020; 3:e202175. doi: 10.1001/jamanetworkopen.2020.2175

• PubMed
Randhawa MS, Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: A systematic review and meta-analysis. JAMA Netw Open 2020; 3:e202175. doi: 10.1001/jamanetworkopen.2020.2175)| false
• Search Google Scholar
• Export Citation

Mookadam M, et al. Novel anticoagulants in atrial fibrillation: A primer for the primary physician. J Am Board Fam Med 2015; 28: 510–522. doi: 10.3122/jabfm.2015.04.140297

• PubMed
Mookadam M, Novel anticoagulants in atrial fibrillation: A primer for the primary physician. J Am Board Fam Med 2015; 28: 510–522. doi: 10.3122/jabfm.2015.04.140297)| false
• Search Google Scholar
• Export Citation

Vu A, et al. Critical analysis of apixaban dose adjustment criteria. Clin Appl Thromb Hemost 2021; 27:10760296211021158. doi: 10.1177/10760296211021158

• PubMed
Vu A, Critical analysis of apixaban dose adjustment criteria. Clin Appl Thromb Hemost 2021; 27:10760296211021158. doi: 10.1177/10760296211021158)| false
• Search Google Scholar
• Export Citation

Mavrakanas TA, et al. Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin J Am Soc Nephrol 2020; 15: 1146–1154. doi: 10.2215/CJN.11650919

• PubMed
Mavrakanas TA, Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin J Am Soc Nephrol 2020; 15: 1146–1154. doi: 10.2215/CJN.11650919)| false
• Search Google Scholar
• Export Citation

Reed D, et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2018; 2: 291–298. doi: 10.1002/rth2.12083

• PubMed
Reed D, Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2018; 2: 291–298. doi: 10.1002/rth2.12083)| false
• Search Google Scholar
• Export Citation

Siontis KC, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018; 138: 1519–1529. doi: 10.1161/CIRCULATIONAHA.118.035418

• PubMed
Siontis KC, Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018; 138: 1519–1529. doi: 10.1161/CIRCULATIONAHA.118.035418)| false
• Search Google Scholar
• Export Citation

Chokesuwattanaskul R, et al. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis. Pacing Clin Electrophysiol 2018; 41: 627–634. doi: 10.1111/pace.13331

• PubMed
Chokesuwattanaskul R, Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis. Pacing Clin Electrophysiol 2018; 41: 627–634. doi: 10.1111/pace.13331)| false
• Search Google Scholar
• Export Citation

Kuno T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol 2020; 75: 273–285. doi: 10.1016/j.jacc.2019.10.059

• PubMed
Kuno T, Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol 2020; 75: 273–285. doi: 10.1016/j.jacc.2019.10.059)| false
• Search Google Scholar
• Export Citation

Chan KE, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 13: 972–979. doi: 10.1161/CIRCULATIONAHA.114.014113

• PubMed
Chan KE, Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 13: 972–979. doi: 10.1161/CIRCULATIONAHA.114.014113)| false
• Search Google Scholar
• Export Citation

De Vriese AS, et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 91–98. doi: 10.1053/j.ajkd.2015.01.022

• PubMed
De Vriese AS, Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 91–98. doi: 10.1053/j.ajkd.2015.01.022)| false
• Search Google Scholar
• Export Citation

Wang X, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628–636. doi: 10.1002/jcph.628

• PubMed
Wang X, Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628–636. doi: 10.1002/jcph.628)| false
• Search Google Scholar
• Export Citation

Mavrakanas TA, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28: 2241–2248. doi: 10.1681/ASN.2016090980

• PubMed
Mavrakanas TA, Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28: 2241–2248. doi: 10.1681/ASN.2016090980)| false
• Search Google Scholar
• Export Citation

Bohula EA, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134:24–36. doi: 10.1161/CIRCULATIONAHA.116.022361

• PubMed
Bohula EA, Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134:24–36. doi: 10.1161/CIRCULATIONAHA.116.022361)| false
• Search Google Scholar
• Export Citation